IRVING LONDON, M.D.
Medical Practice in Cambridge, MA
License number
Massachusetts 36455
Category
Medical Practice
Type
Hematology
Address
Address
E25-551 Mit, Cambridge, MA 02139
Phone
(617) 253-4305
Professional information
Irving Myer London, Cambridge MA
Specialties:
Hematologist
Address:
45 Carleton St, Cambridge, MA 02142
Dna Encoding The Heme-Regulated Eukaryotic Initiation Factor 2.Alpha. Kinase
US Patent:
5690930, Nov 25, 1997
Filed:
Apr 10, 1996
Appl. No.:
8/630524
Inventors:
Jane-Jane Chen - Belmont MA
Irving M. London - Cambridge MA
Irving M. London - Cambridge MA
Assignee:
Massachusetts Institute of Technology - Cambridge MA
International Classification:
A61K 3845
US Classification:
424 945
Abstract:
The cDNA which encodes heme-regulated eIF-2. alpha. kinase (HRI) has been cloned from a lambda Zap II cDNA library of rabbit reticulocytes. The rabbit HRI cDNA is highly homologous to human HRI and hybridizes to the human HRI DNA under moderately stringent conditions. The rabbit HRI cDNA contains 2729 amino acids. In vitro translation of HRI mRNA transcribed from HRI cDNA yields a 90 kDa polypeptide with eIF-2. alpha. kinase activity. Since HRI is a potent inhibitor of protein synthesis, it is anti-proliferative in nature. In addition, the unusually high degree of homology of HRI to three protein kinases involved in the regulation of cell division suggests that HRI plays a direct role in the regulation of cell division. Since regulation of protein synthesis is vital for cell growth and differentiation, the cDNA can be inserted into cells to manipulate proliferation and differentiation, especially of cells that are proliferating in an uncontrolled manner or characterized by arrested differentiation, such as some of the types of cancers. Initiation of protein synthesis can also be regulated by another eIF-2. alpha.
Retroviral Vectors For Transducing .Beta.-Globin Gene And .Beta.-Locus Control Region Derivatives
US Patent:
5631162, May 20, 1997
Filed:
Jun 11, 1993
Appl. No.:
8/076090
Inventors:
Philippe LeBoulch - Cambridge MA
Irving M. London - Cambridge MA
Dorothy Tuan - Newton MA
Irving M. London - Cambridge MA
Dorothy Tuan - Newton MA
Assignee:
Massachusetts Institute of Technology - Cambridge MA
International Classification:
C12N 1564, C12N 1568, C12N 1585, C12N 1586
US Classification:
4353201
Abstract:
A process and means for the design and the optimization of retroviral vectors transducing human. beta. -globin gene and. beta. -Locus Control Region (. beta. -LCR) derivatives, hereafter referred to as [. beta. -globin/LCR] retroviruses, which successfully meet the following criteria required for gene therapy applications: (1) stability of proviral transmission (low frequency of rearrangements similar to retroviral vectors considered stable in the art) upon infection of cell-lines and murine bone marrow cells, (2) improved viral titer, thereby allowing successful infection of bone marrow cells, and (3) high erythroid expression of the transduced human. beta. -globin gene, are described, along with specific constructs.
Dna Encoding The Heme-Regulated Eukaryotic Initiation Factor 2.Alpha. Kinase
US Patent:
5525513, Jun 11, 1996
Filed:
Aug 31, 1992
Appl. No.:
7/938782
Inventors:
Jane-Jane Chen - Belmont MA
Irving M. London - Cambridge MA
Irving M. London - Cambridge MA
Assignee:
Massachusetts Institute of Technology - Cambridge MA
International Classification:
C12N 1554, C12N 1563
US Classification:
4353201
Abstract:
The cDNA which encodes heme-regulated eIF-2. alpha. kinase (HRI) has been cloned from a lambda Zap II cDNa of rabbit reticulocytes. The rabbit HRI cDNA is highly homologous to human HRI and hybridizes to the human HRI DNA under moderately stringent conditions. The rabbit HRI cDNA contains 2729 amino acids. In vitro translation of HRI mRNA transcribed from HRI cDNA yields a 90 kDa polypeptide with eIF-2. alpha. kinase activity. Since HRI is a potent inhibitor or protein synthesis, it is anti-proliferative in nature. In addition, the unusually high degree of homology of HRI to three protein kinases involved in the regulation of cell division suggests that HRI plays a direct role in the regulation of cell division. Since regulation of protein synthesis is vital of cell growth and differentiation, the cDNA can be inserted into cells to manipulate proliferation and differentiation, especially of cells that are proliferating in an uncontrolled manner of characterized by arrested differentiation, such as some of the types of cancers. Deletion mutants of HRI cDNA can be constructed that are insensitive to regulation by heme, which should be more effective than native HRI in its anti-viral and anti-proliferative action.
Human Erythroid-Specific Transcriptional Enhancer
US Patent:
5126260, Jun 30, 1992
Filed:
Dec 4, 1990
Appl. No.:
7/622356
Inventors:
Dorothy Y. H. Tuan - Newton MA
Irving M. London - Cambridge MA
William B. Solomon - New York NY
Irving M. London - Cambridge MA
William B. Solomon - New York NY
Assignee:
Massachusetts Institute of Technology - Cambridge MA
International Classification:
C12N 1585, C12N 516, C12N 1500, C12P 2102
US Classification:
4352402
Abstract:
A human erythroid specific enhancer element is described. The enhancer element can be used to enhance transcription of a structural gene in erythroid cells. Methods for gene therapy employing the enhancer element are also disclosed.
Compositions And Methods For Treating Sickle Cell Disease
US Patent:
5861488, Jan 19, 1999
Filed:
Sep 23, 1997
Appl. No.:
8/935648
Inventors:
Philippe LeBoulch - Cambridge MA
Irving M. London - Cambridge MA
Irving M. London - Cambridge MA
Assignee:
Massachusetts Institute of Technology - Cambridge MA
International Classification:
C07K 14805, C12P 2106
US Classification:
530385
Abstract:
Gene therapy methods and compositions for high level expression of anti-sickling globin proteins in erythroid cells for treating Sickle Cell disease are described.
Compositions And Methods For Treating Sickle Cell Disease
US Patent:
6051402, Apr 18, 2000
Filed:
Jan 19, 1999
Appl. No.:
9/234009
Inventors:
Philippe LeBoulch - Cambridge MA
Irving M. London - Cambridge MA
Irving M. London - Cambridge MA
Assignee:
Massachusetts Institute of Technology - Cambridge MA
International Classification:
C12P 2106, C07H 1700, C07K 14805
US Classification:
435 691
Abstract:
Gene therapy methods and compositions for high level expression of anti-sickling globin proteins in erythroid cells for treating Sickle Cell disease are described.